Anges Inc.
Basic information
- Head office
- 7-15, Asagi, Saiho, Ibaraki City, Osaka Prefecture
- Chief executive
- Hidetaka Yamada
- Capital
- 40,228,000,000 (402 100 million)
- Employees (non-consolidated)
- 33 people
- Employees (consolidated)
- 56 people
- Start date
- 1999-12-17
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| アンジェス インク | ||||||||
|
|
||||||||
| アンジェス ユーロ リミテッド | ||||||||
| ジェノミディア株式会社 | ||||||||
| MediGene Inc. | ||||||||
| Eiger BioPharmaceuticals Inc. | ||||||||
|
|
||||||||
|
|
Network
History
Established MedGene Inc. in Izumi City, Osaka Prefecture, for the purpose of researching and developing research reagents for gene therapy products, nucleic acid pharmaceuticals, and gene function analysis
Established MedGene Inc. in Izumi City, Osaka Prefecture in December 1999
Changed the trade name to MedGene BioScience Inc.
Opened a Tokyo branch in Minato Ward, Tokyo
Changed the trade name to Anges MG Inc.
Established Anges Inc. (consolidated subsidiary) in Maryland, USA, for clinical development in the United States
Established AnGes Inc. (consolidated subsidiary) in Maryland, USA
Established Anges Euro Limited (consolidated subsidiary) in Sussex, UK, for clinical development in Europe
Established AnGes Euro Limited (consolidated subsidiary) in Sussex, Europe
Established Genomedia Inc. (consolidated subsidiary) in Toyonaka, Osaka Prefecture, for discovery and drug development of therapeutic and diagnostic genes
Established Genomedia Inc. (consolidated subsidiary) in Toyonaka, Osaka Prefecture
Listed on the Tokyo Stock Exchange Mothers Market
Reorganized within the group using a company split system, consolidating human resources, assets, and intellectual property related to the HVJ-E non-viral vector business, which is dispersed within the group (the company and its consolidated subsidiary Genomedia Inc.)
Reorganized the group structure to consolidate the HVJ-E non-viral vector business into Genomedia Inc.
Changed the trade name to Anges MG Corporation
Relocated headquarters and research institute to Ibaraki City, Osaka Prefecture
Genomedia Inc. relocated its headquarters to Ibaraki City, Osaka Prefecture
Partnered with BioMarin Pharmaceutical Inc. (USA) for the sale of Mucopolysaccharidosis Type VI drug (Naglazyme®) domestically
Partnered with Biomarlin Pharmaceuticals Inc. (USA) for the domestic sales of Mucopolysaccharidosis Type VI drug (Naglazyme®)
Applied for approval of HGF gene therapy drug for severe ischemic limb and Buerger's disease in Japan
Applied for approval of HGF gene therapy drug domestically
Started domestic sales of Mucopolysaccharidosis Type VI drug (Naglazyme®)
Started domestic sales of Mucopolysaccharidosis Type VI drug (Naglazyme®)
Application for manufacturing and sales of HGF gene therapy drugs in Japan has been withdrawn
Signed a license agreement with Shionogi & Co., Ltd. to jointly develop NF-κB decoy oligo DNA in the field of atopic dermatitis
Signed a license agreement with Shionogi & Co., Ltd. for joint development of NF-κB decoy oligo DNA in the field of atopic dermatitis
Signed an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for HGF gene therapy products targeting peripheral vascular diseases in the United States
Signed a sales rights agreement for HGF gene therapy product in the US with Mitsubishi Tanabe Pharma Corporation
Transferred shares of Genomedia Inc. to Ishihara Sangyo Co., Ltd.
Transferred shares of Genomedia Inc. to Ishihara Sangyo
May 23rd was designated as 'Rare Disease Day' to deliver and deepen understanding of the thoughts of patients facing rare diseases and their families, taking the opportunity of the Rare Disease Act enacted in 2014.
Signed an exclusive sales rights agreement with Mitsubishi Tanabe Pharma Corporation for HGF gene therapy products targeting peripheral vascular diseases in Japan
Signed a sales rights agreement for HGF gene therapy product in Japan with Mitsubishi Tanabe Pharma Corporation
Changed trade name to AnGes Inc.
Applied for manufacturing and sales approval of HGF gene therapy products for chronic arterial occlusive disease using conditional and time-limited approval system
Applied for approval of HGF gene therapy product
Obtained conditional and time-limited manufacturing and sales approval for HGF gene therapy products
Received conditional and time-limited approval for HGF gene therapy product
Launched HGF gene therapy products domestically
Launched HGF gene therapy product domestically
Started development of a DNA vaccine for COVID-19 in collaboration with Osaka University
Started clinical trials of AV-001 co-developed with Vasomune as a treatment for COVID-19
Started clinical trials for AV-001 co-developed with Vasomune as a treatment for COVID-19
Established a health examination center (now AnGes Clinical Research Laboratory) mainly for rare genetic disease testing
Established a subsidiary, EmendoBio
Signed a sales agreement in Japan for the rare disease drug Zokinvi (Ronafernumab) with Eiger BioPharmaceuticals Inc.
Established a health inspection laboratory (now AnGes Clinical Research Laboratory)
Suspended development of the COVID-19 DNA vaccine in collaboration with Osaka University
Canceled joint development of COVID-19 vaccine with Osaka University
Applied for manufacturing and sales approval of the aging disease treatment drug Zokinvi
Applied for manufacturing and sales approval of HGF gene therapy product Colategen
Started administration in Phase II clinical trial of NF-κB decoy oligo DNA for the treatment of chronic intervertebral disc-related low back pain
Started Phase II clinical trial in Japan for NF-κB decoy oligodeoxynucleotide for chronic intervertebral disc-related low back pain
Obtained manufacturing and sales approval for the aging disease treatment drug Zokinvi
Started sales of the aging disease treatment drug Zokinvi
Sales of 'Zokinvi', a treatment for progeria. Zokinvi is a treatment for Hutchinson-Gilford Progeria Syndrome (HGPS), a very rare genetic disorder, and Progeroid Laminopathy (PDPL), both of which cause rapid aging in children. AnGes obtained manufacturing and sales approval for these treatments in Japan and started sales in May 2024.
Withdrew application for approval and discontinued sales of HGF gene therapy product Colategen
Agreement to terminate the sales contract of 'Collegen' in Japan and the United States with Mitsubishi Tanabe Pharma Corporation
Withdrawn application for approval of HGF gene therapy product "Collagen" and ceased sales. Agreed to end sales contract
HGF gene therapy product designated as a breakthrough therapy by the US FDA
Termination of exclusive sales rights agreement for HGF gene therapy product in Japan with Mitsubishi Tanabe Pharma Corporation
Agreed to terminate sales contract for "Collagen"
Termination of exclusive sales rights agreement for HGF gene therapy product in the US with Mitsubishi Tanabe Pharma Corporation
Termination of sales contract for HGF gene therapy product in the United States
Decision to develop HGF gene therapy product in the US and conclusion of raw drug supply agreement with Bayer Ingelheim Biopharmaceuticals
Decided on development policy for HGF gene therapy product in the United States and concluded raw drug supply contract
News
There is no news.
Public records
National Tax Agency basic information6120901013446
- Trade name
- アンジェス株式会社
- Trade name (kana)
- アンジェス
- Name in English
- Corporation type
- 301
- Address
- 〒567-0085 大阪府茨木市彩都あさぎ７丁目７番１５号
- Postal code
- 5670085
- Prefecture code
- 27
- City code
- 211
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2018-08-10
- Change date
- 2017-07-03
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 11
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 4290360
METI gBizINFO6120901013446
- Corporate number
- 6120901013446
- Trade name
- アンジェス株式会社
- Trade name (kana)
- アンジェス
- Trade name (alphabet)
- AnGes, Inc.
- Registry closure date
- Reason for registry closure
- Registered address
- 大阪府茨木市彩都あさぎ７丁目７番１５号
- Postal code
- 5670085
- Prefecture
- 大阪府
- Prefecture code
- 27
- City or district
- 茨木市
- City code
- 211
- Street address
- 彩都あさぎ７丁目７番１５号
- Organisation type
- 301
- Processing type
- 11
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 山 田 英
- Capital
- 40228661000
- Employees
- 35
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- 1999-12-17
- Unified government qualification - grade
- ||C|
- Unified government qualification - business items
- 315
- Update date
- 2026-05-01
- Key information
- 6120901013446